Lavene D, Weiss Y A, Safar M E, Loria Y, Agorus N, Georges D, Milliez P L
J Clin Pharmacol. 1977 Aug-Sep;17(8-9):501-8. doi: 10.1002/j.1552-4604.1977.tb05643.x.
The intravenous and oral pharmacokinetics and the hepatic extraction ratio of pindolol were determined in 24 hypertensive patients with normal or impaired renal function. In patients with normal renal function, the total clearance was the sum of equal parts of the renal and nonrenal clearances. The nonrenal clearance was found to be equal to the hepatic clearance directly measured from the hepatic extraction ratio. Compared to patients with normal renal function, patients with chronic renal failure exhibited (i) unchanged K12 and K21 and nonrenal clearances, and (ii) significantly decreased values in half-life of the beta phase, Kel, and total renal clearance. The renal clearance was positively correlated (P less than 0.01) to the creatinine clearance. Bioavailability was significantly reduced (P less than 0.01) in the patients with renal failure. Assuming that the nonrenal clearance was equal to the hepatic clearance, the study provides evidence that, in patients with renal insufficiency, (i) no increased metabolism accompanies the decrease in renal function, and (ii) decreased availability is due to reduced absorption.
在24例肾功能正常或受损的高血压患者中测定了吲哚洛尔的静脉和口服药代动力学以及肝脏提取率。在肾功能正常的患者中,总清除率是肾清除率和非肾清除率各占一半之和。发现非肾清除率等于直接从肝脏提取率测得的肝脏清除率。与肾功能正常的患者相比,慢性肾衰竭患者表现为:(i)K12和K21以及非肾清除率不变,(ii)β相半衰期、Kel和总肾清除率的值显著降低。肾清除率与肌酐清除率呈正相关(P<0.01)。肾衰竭患者的生物利用度显著降低(P<0.01)。假设非肾清除率等于肝脏清除率,该研究提供的证据表明,在肾功能不全的患者中,(i)肾功能下降时代谢没有增加,(ii)药物可利用度降低是由于吸收减少。